Development of locus specific sub‐clone separation by fluorescence in situ hybridization in suspension in chronic lymphocytic leukemia

Intra‐tumor genetic heterogeneity is a hallmark of cancer. The ability to monitor and analyze these sub‐clonal cell populations can be considered key to successful treatment, particularly in the modern era of targeted therapies. Although advances in sequencing technologies have significantly improve...

Full description

Saved in:
Bibliographic Details
Published in:Cytometry. Part A 2017-11, Vol.91 (11), p.1088-1095
Main Authors: Do, Cuc H., Bailey, Sheree, Macardle, Cindy, Thurgood, Lauren A., Lower, Karen M., Kuss, Bryone J.
Format: Article
Language:English
Subjects:
17p locus specific probes
Artificial chromosomes
Bacteria
Cancer
Chromosome 17
Chromosome Deletion
Chromosomes, Human, Pair 17 - genetics
Chronic lymphocytic leukemia
CLL
Clonal deletion
Clone Cells - pathology
Cloning
Cytometry
Diagnostic systems
FISH‐IS
Flow cytometry
Flow Cytometry - methods
Fluorescence
Fluorescence in situ hybridization
Fluorescent indicators
Gene deletion
Gene polymorphism
Gene sequencing
Genetic analysis
Genetic Heterogeneity
Heterogeneity
High-Throughput Screening Assays - methods
Humans
Hybridization
Image Stream X
In Situ Hybridization, Fluorescence - methods
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell - genetics
Leukemia, Lymphocytic, Chronic, B-Cell - pathology
Loci
low frequency
Lymphatic leukemia
Mutation - genetics
p53 Protein
Polymorphism
Populations
Prognosis
Single-nucleotide polymorphism
sub‐clone separation
Tumor Suppressor Protein p53 - genetics
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intra‐tumor genetic heterogeneity is a hallmark of cancer. The ability to monitor and analyze these sub‐clonal cell populations can be considered key to successful treatment, particularly in the modern era of targeted therapies. Although advances in sequencing technologies have significantly improved our ability to analyze the mutational landscape of tumors, this utility is reduced when considering small, but clinically significant sub‐clones, that is, those representing
ISSN:1552-4922
1552-4930
DOI:10.1002/cyto.a.23264